SCHEMBL6090873

SCHEMBL6090873

CCC(O)(CC)c1ccc2nc(C)[nH]c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
GAA P10253 2/20 0.59
HSD17B10 Q99714 1/20 0.59
ALDH1A1 P00352 4/20 0.50
HSP90AA1 P07900 1/20 0.49
ESR2 Q92731 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 3/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 4/20 0.44
POLB P06746 4/20 0.44
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
SCN10A Q9Y5Y9 4/20 0.43
LCK P06239 3/20 0.43
TXK P42681 3/20 0.43
SYK P43405 3/20 0.43
ITK Q08881 3/20 0.43
MEN1 O00255 2/20 0.42
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090961 0.81 KDM4E (0.52) MAPTGAAHSD17B10ALDH1A1KDM4E
SCHEMBL805057 0.78 GAA (0.68) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL12020707 0.77 MAPT (0.76) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL24589283 0.76 MAPT (0.73) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL10573938 0.75 MAPT (0.59) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL3266151 0.73 MAPT (0.45) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL10235429 0.73 MAPT (0.45) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL6092073 0.72 CYP2A6 (0.49) MAPTGAAALDH1A1TDP1KDM4E
SCHEMBL2757174 0.71 ALDH1A1 (0.58) MAPTGAAHSD17B10ALDH1A1HSP90AA1
SCHEMBL10574938 0.71 MAPT (0.50) MAPTGAAHSD17B10ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors ELI LILLY AND COMPANY (US) 2006-10-19 US disclosed
EP-1597254-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS Eli Lilly and Company (US) 2005-11-23 EP disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors NR3C2, NR5A1, MC2R MAPT 4025/4885GAA 4762/4885HSD17B10 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.